Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.
Race, age, and sex were predictors of survival in patients with SCC of the upper esophagus, highlighting the need to address disparities in esophageal SCC management.